Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus PENICILLIN G POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus PENICILLIN G POTASSIUM.
CYCLAPEN-W vs PENICILLIN G POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic